Analysts assess fallout after AstraZeneca halts PhIII Covid-19 vaccine dosing to probe a possible serious adverse event
Investigators at AstraZeneca have ordered a halt to dosing their closely-watched Covid-19 vaccine in order to probe a potentially severe adverse event — reportedly involving inflammation of the spinal cord — suffered by one of the trial participants.
In a statement out Tuesday evening, a spokesman for the pharma giant told Endpoints News that the study had been put on hold to investigate an illness. Later Tuesday, they sent a revised statement, which noted that the halt is voluntary, not ordered by regulators. It reads:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
